Validation of UHPLC-MS/MS methods for the determination of kaempferol and its metabolite 4-hydroxyphenyl acetic acid, and application to in vitro blood-brain barrier and intestinal drug permeability studies

Journal of Pharmaceutical and Biomedical Analysis

Volumn 128, Issue , 2016, Pages 264-274

  Moradi Afrapoli, Fahimeh ^a,b   Oufir, Mouhssin ^a   Walter, Fruzsina R ^c   Deli, Maria A ^c   Smiesko, Martin ^a   Zabela, Volha ^a   Butterweck, Veronika ^d,e   Hamburger, Matthias ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

4 HPAA; Blood brain barrier; Caco 2 model; Kaempferol; LC MS MS; Method validation

Indexed keywords

ACETIC ACID DERIVATIVE; KAEMPFEROL; 4-HYDROXYPHENYLACETIC ACID; KAEMPFEROL DERIVATIVE; PHENYLACETIC ACID DERIVATIVE;

ACCURACY; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; COLORECTAL CARCINOMA; COMPUTER MODEL; CONTROLLED STUDY; DILUTION; DRUG PENETRATION; GLIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MASS SPECTROMETRY; NONHUMAN; PERICYTE; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION STUDY; ANIMAL; CACO-2 CELL LINE; CALIBRATION; CELL CULTURE; CHEMISTRY; COCULTURE; COMPUTER SIMULATION; METABOLISM; REPRODUCIBILITY; STANDARD; TANDEM MASS SPECTROMETRY; WISTAR RAT;

ANIMALS; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CALIBRATION; CELLS, CULTURED; COCULTURE TECHNIQUES; COMPUTER SIMULATION; HUMANS; INTESTINAL ABSORPTION; KAEMPFEROLS; PHENYLACETATES; RATS; RATS, WISTAR; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84973163775     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2016.05.039     Document Type: Article

References (62)

1. Rice-Evans C.A., Packer L. Flavonoids in Health and Disease 2003, Marcel Dekker, Inc., New York. second ed.
2. Harborne J.B., Williams C.A. Advances in flavonoid research since 1992. Phytochemistry 2000, 55:481-504.
3. Gu R., Wang Y., Long B., Kennelly E., Wu S., Liu B., Li P., Long C. Prospecting for bioactive constituents from traditional medicinal plants through ethnobotanical approaches. Biol. Pharm. Bull. 2014, 37:903-915.
4. Birt D.F., Hendrich S., Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Therapeut. 2001, 90:157-177.
5. Chen H., Yao K., Nadas J., Bode A.M., Malakhova M., Oi N., Li H., Lubet R.A., Dong Z. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One 2012, 7:e38261.
6. Cook N., Samman S. Flavonoids-chemistry metabolism, cardioprotective effects, and dietary sources. J. Nutr. Biochem. 1996, 7:66-76.
7. Islam M.A., Schmidt R.W., Gunaseelan S., Sanchez A. An update on the cardiovascular effects of quercetin, a plant flavonoid. Curr. Nutr. Food Sci. 2014, 10:36-48.
8. Castell M., Pérez-Cano F., Abril-Gil M., Franch A. Flavonoids on allergy. Curr. Pharm. Des. 2014, 20:973-987.
9. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004, 3:205-214.
10. Grundmann O., Nakajima J.I., Seo S., Butterweck V. Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test. J. Ethnopharmacol. 2007, 110:406-411.
11. Zhang-Jin Z. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci. 2004, 75:1659-1699.
12. Aguirre-Hernández E., Martínez A., González-Trujano M., Moreno J., Vibrans H., Soto-Hernández M. Pharmacological evaluation of the anxiolytic and sedative effects of Tilia americana L. var. mexicana in mice. J. Ethnopharmacol. 2007, 109:140-145.
13. Kumar S., Sharma A. Anti-anxiety activity studies of various extracts of Turnera aphrodisiaca Ward. J. Herb. Pharmacother. 2005, 5:13-21.
14. Jung J.W., Ahn N.Y., Oh H.R., Lee B.K., Lee K.J., Kim S.Y., Cheong J.H., Ryu J.H. Anxiolytic effects of the aqueous extract of Uncaria rhynchophylla. J. Ethnopharmacol. 2006, 108:193-197.
15. Chimenti F., Cottiglia F., Bonsignore L., Casu L., Casu M., Floris C., Secci D., Bolasco A., Chimenti P., Granese A. Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and computational study. J. Nat. Prod. 2006, 69:945-949.
16. Sloley B., Urichuk L., Morley P., Durkin J., Shan J., Pang P., Coutts R. Identification of kaempferol as a monoamine oxidase inhibitor and potential neuroprotectant in extracts of Ginkgo biloba leaves. J. Pharm. Pharmacol. 2000, 52:451-459.
17. Marder M., Estiú G., Blanch L.B., Viola H., Wasowski C., Medina J.H., Paladini A.C. Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepine binding site of the GABA A receptor complex. Bioorgan. Med. Chem. 2001, 9:323-335.
18. Medina J.H., Viola H., Wolfman C., Marder M., Wasowski C., Calvo D., Paladini A.C. Overview-flavonoids: a new family of benzodiazepine receptor ligands. Neurochem. Res. 1997, 22:419-425.
19. Wang F., Huen Y., Michael S., Tsang S.Y., Xue H. Neuroactive flavonoids interacting with GABAA receptor complex. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:575-585.
20. Keppler K., Hein E.M., Humpf H.U. Metabolism of quercetin and rutin by the pig caecal microflora prepared by freeze-preservation. Mol. Nutr. Food Res. 2006, 50:686-695.
21. Labib S., Hummel S., Richling E., Humpf H.U., Schreier P. Use of the pig caecum model to mimic the human intestinal metabolism of hispidulin and related compounds. Mol. Nutr. Food Res. 2006, 50:78-86.
22. Blaut M., Schoefer L., Braune A. Transformation of flavonoids by intestinal microorganisms. Int. J. Vitam. Nutr. Res. 2003, 73:79-87.
23. Griffiths L., Smith G. Metabolism of myricetin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem. J. 1972, 130:141-151.
24. Vissiennon C., Nieber K., Kelber O., Butterweck V. Route of administration determines the anxiolytic activity of the flavonols kaempferol, quercetin and myricetin-are they prodrugs?. J. Nutr. Biochem. 2012, 23:733-740.
25. Lindemann L., Hoener M.C. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol. Sci. 2005, 26:274-281.
26. Boulton A.A. Some aspects of basic psychopharmacology: the trace amines. Prog. Neuro-Psychopharmacol. 1982, 6:563-570.
27. Boulton A.A., Davis B.A., Peter H.Y., Wormith J.S., Addington D. Trace acid levels in the plasma and MAO activity in the platelets of violent offenders. Psychiatry Res. 1983, 8:19-23.
28. Dourish C.T., Davis B., Dyck L., Jones R., Boulton A. Alterations in trace amine and trace acid concentrations in isolated aggressive mice. Pharmacol. Biochem. Behav. 1982, 17:1291-1294.
29. Juorio A., McQuade P. Effects of various antipsychotic drugs upon the striatal concentrations of para-hydroxyphenylacetic acid and meta-hydroxyphenylacetic acid in the mouse. Br. J. Pharmacol. 1983, 80:581-585.
30. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Intervention 2003, 3:90-105.
31. Chen J., Lin H., Hu M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J. Pharmacol. Exp. Ther. 2003, 304:1228-1235.
32. Olthof M.R., Hollman P.C., Vree T.B., Katan M.B. Bioavailabilities of quercetin-3-glucoside and quercetin-4'-glucoside do not differ in humans. J. Nutr. 2000, 130:1200-1203.
33. Konishi Y. Transepithelial transport of microbial metabolites of quercetin in intestinal caco-2 cell monolayers. J. Agr. Food Chem. 2005, 53:601-607.
34. Murota K., Shimizu S., Miyamoto S., Izumi T., Obata A., Kikuchi M., Terao J. Unique uptake and transport of isoflavone aglycones by human intestinal caco-2 cells: comparison of isoflavonoids and flavonoids. J. Nutr. 2002, 132:1956-1961.
35. Tian X.J., Yang X.W., Yang X., Wang K. Studies of intestinal permeability of 36 flavonoids using caco-2 cell monolayer model. Int. J. Pharm. 2009, 367:58-64.
36. Faria A., Meireles M., Fernandes I., Santos-Buelga C., Gonzalez-Manzano S., Dueñas M., de Freitas V., Mateus N., Calhau C. Flavonoid metabolites transport across a human BBB model. Food Chem. 2014, 149:190-196.
37. Yang Y., Bai L., Li X., Xiong J., Xu P., Guo C., Xue M. Transport of active flavonoids, based on cytotoxicity and lipophilicity: an evaluation using the blood-brain barrier cell and caco-2 cell models. Toxicol. in vitro 2014, 28:388-396.
38. Youdim K.A., Qaiser M.Z., Begley D.J., Rice-Evans C.A., Abbott N.J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med. 2004, 36:592-604.
39. Youdim K.A., Dobbie M.S., Kuhnle G., Proteggente A.R., Abbott N.J., Rice-Evans C. Interaction between flavonoids and the blood-brain barrier: in vitro studies. J. Neurochem. 2003, 85:180-192.
40. Barrington R., Williamson G., Bennett R.N., Davis B.D., Brodbelt J.S., Kroon P.A. Absorption conjugation and efflux of the flavonoids, kaempferol and galangin, using the intestinal CaCo-2/TC7 cell model. J. Funct. Foods 2009, 1:74-87.
41. C. FDA Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, In, Food and Drug Administration 2001, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV).
42. EMA, Guideline on bioanalytical method validation, in, European Medicines Agency (EMEA/CHMP/EWP/192217/2009), London, 2011.
43. Kapitza S.B., Michel B.R., van Hoogevest P., Leigh M.L., Imanidis G. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the caco-2 cell model. Eur. J. Pharm. Biopharm. 2007, 66:146-158.
44. Konishi Y., Hagiwara K., Shimizu M. Transepithelial transport of fluorescein in caco-2 cell monolayers and use of such transport in vitro evaluation of phenolic acid availability. Biosci. Biotech. Biochem. 2002, 66:2449-2457.
45. Kanaan M., Daali Y., Dayer P., Desmeules J. Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. Basic Clin. Pharmacol. 2009, 105:199-206.
46. Eigenmann D.E., Xue G., Kim K.S., Moses A.V., Hamburger M., Oufir M. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19 and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 2013, 10:1-17.
47. Jähne E.A., Eigenmann D.E., Culot M., Cecchelli R., Walter F.R., Deli M.A., Tremmel R., Fricker G., Smiesko M., Hamburger M., Oufir M. Development and validation of a LC-MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood-brain barrier models. J. Pharm. Biomed. Anal. 2014, 98:235-246.
48. Eigenmann D.E., Jähne E.A., Smiesko M., Hamburger M., Oufir Mouhssin Validation of an immortalized human (hBMEC) in vitro blood-brain barrier model. Anal. Bioanal. Chem. 2016, 8:2095-2107.
49. Veszelka S., Tóth A.E., Walter F.R., Datki Z., Mózes E., Fülöp L., Bozsó Z., Hellinger É., Vastag M., Orsolits B. Docosahexaenoic acid reduces amyloid-β induced toxicity in cells of the neurovascular unit. J. Alzheimers Dis. 2013, 36:487-501.
50. Nakagawa S., Deli M.A., Kawaguchi H., Shimizudani T., Shimono T., Kittel A., Tanaka K., Niwa M. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 2009, 54:253-263.
51. Perriere N., Demeuse P., Garcia E., Regina A., Debray M., Andreux J.P., Couvreur P., Scherrmann J.M., Temsamani J., Couraud P.O. Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J. Neurochem. 2005, 93:279-289.
52. Deli M.A., Ábrahám C.S., Kataoka Y., Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell. Mol. Neurobiol. 2005, 25:59-127.
53. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2012, 64:4-17.
54. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45:2615-2623.
55. van de Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Targeting 1998, 6:151-165.
56. Matei I., Tablet C., Ionescu S., Hillebrand M. Close-lying pKa values of kaempferol determined by second-derivative synchronous fluorescence. Rev. Roum. Chim. 2014, 59:401-405.
57. Smith R.M., Martell A.E. Critically selected stability constants of metal complexes. NIST Stand. Reference Database 2004, 46:8.
58. Ott M., Huls M., Cornelius M.G., Fricker G. St. John's wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier. Pharm. Res. 2010, 27:811-822.
59. Foster J.A., McVey Neufeld K.A. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013, 36:305-312.
60. Reardon S. Gut-brain link grabs neuroscientists. Nature 2014, 515:175-177.
61. Serra A., Macià A., Romero M.P., Reguant J., Ortega N., Motilva M.J. Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem. 2012, 130:383-393.
62. Chen M.L., Amidon G.L., Benet L.Z., Lennernas H., Yu L.X. The BCS BDDCS, and regulatory guidances. Pharm. Res. 2011, 28:1774-1778.